3 Takeaways As China Rolls Out Its Version Of ANDA Disputes
A year after China launched a system for generic-drug patent disputes modeled on the U.S. Hatch-Waxman Act, the first decisions have come down. Here are the key things to know about...To view the full article, register now.
Already a subscriber? Click here to view full article